<DOC>
	<DOC>NCT02552940</DOC>
	<brief_summary>This observational trial will evaluate the effectiveness, the consistency of evaluation scores, quality of life, safety and tolerability of TCZ administered subcutaneously (SC) in participants with RA in daily clinical practice.</brief_summary>
	<brief_title>An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Participants naive to TCZ or who have received TCZ SC treatment within 8 weeks prior to the enrolment visit can be included Participants in whom the treating physician has made the decision to commence TCZ SC in accordance with the label and reimbursement criteria Participants who have received TCZ &gt;8 weeks prior to the enrolment visit Participants who have previously received TCZ SC Participants who have received treatment with any investigational agent within 4 weeks before starting treatment with TCZ SC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>